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A randomized placebo-controlled trial of
oxybutynin for the initial treatment of palmar and
axillary hyperhidrosis
Nelson Wolosker, MD, PhD,a José Ribas Milanez de Campos, MD, PhD,b Paulo Kauffman, MD, PhD,a
and Pedro Puech-Leão, MD, PhD,c São Paulo, SP, Brazil
Introduction: Video-assisted thoracic sympathectomy provides excellent resolution of palmar and axillary hyperhidrosis
but is associated with compensatory hyperhidrosis. Low doses of oxybutynin, an anticholinergic medication that
competitively antagonizes the muscarinic acetylcholine receptor, can be used to treat palmar hyperhidrosis with fewer side
effects.
Objective:This study evaluated the effectiveness and patient satisfaction of oral oxybutynin at low doses (5 mg twice daily)
compared with placebo for treating palmar hyperhidrosis.
Methods: This was prospective, randomized, and controlled study. From December 2010 to February 2011, 50
consecutive patients with palmar hyperhidrosis were treated with oxybutynin or placebo. Data were collected from 50
patients, but 5 (10.0%) were lost to follow-up. During the first week, patients received 2.5 mg of oxybutynin once daily
in the evening. From days 8 to 21, they received 2.5 mg twice daily, and from day 22 to the end of week 6, they received
5 mg twice daily. All patients underwent two evaluations, before and after (6 weeks) the oxybutynin treatment, using a
clinical questionnaire and a clinical protocol for quality of life.
Results: Palmar and axillary hyperhidrosis improved in >70% of the patients, and 47.8% of those presented great
improvement. Plantar hyperhidrosis improved in >90% of the patients. Most patients (65.2%) showed improvements in
their quality of life. The side effects were minor, with dry mouth being the most frequent (47.8%).
Conclusions: Treatment of palmar and axillary hyperhidrosis with oxybutynin is a good initial alternative for treatment
given that it presents good results and improves quality of life. ( J Vasc Surg 2012;55:1696-700.)
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oSweating is a physiologic mechanism of human ther-
moregulation.1 Hyperhidrosis, a disease that affects 2.8% of
the population,1 is a somatic disorder characterized by
exaggerated sweating in a specific region due to hyperfunc-
tioning of the sweat glands. It is frequently triggered by
emotions2 and leads to serious emotional disturbances in
many patients.3
Palmar hyperhidrosis (PH) and axillary hyperhidrosis
(AH) are the most frequent clinical manifestations of pri-
mary hyperhidrosis, and video-assisted thoracic sympathec-
tomy (VATS) is the most appropriate definitive treatment,
with high success rates and low risk.4,5 However, some
complications are observed with surgical denervation, the
most frequent being compensatory hyperhidrosis, with an
incidence 75% and with an unknown pathophysiology.6
In about 30% of patients, compensatory hyperhidrosis is
intense enough to generate dissatisfaction with VATS.7
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1696Different anticholinergic drugs have been used to treat
yperhidrosis, but their use has not become routine be-
ause of side effects.8 Oxybutynin is an anticholinergic drug
hat has been used safely at high doses (up to 15 mg/d) to
reat micturition disorders,9 and a side effect observed in
hese patients has been diminished sudoresis. The use of
xybutynin for treating primary hyperhidrosis has only
een described in three case reports,10-12 one series of 14
atients with compensatory hyperhidrosis after VATS,13
ne publication about facial hyperhidrosis,14 one publica-
ion of AH,15 and one publication of PH.16 To our knowl-
dge, no studies have compared the use of oxybutynin vs
lacebo in the treatment of PH or AH.
Considering that the main treatment for PH and AH is
urgery and that the side effects of such treatment are
ignificant, oxybutynin represents a possible alternative.
his study investigated patient satisfaction and the effec-
iveness of low doses of oxybutynin for treating PH or AH
n a randomized, prospective, blind, and controlled trial.
ETHODS
This was a prospective, randomized, controlled, study
n which the patients were blinded. The institutional pro-
ocol applied to the patients was in accordance with the
rinciples of the Ethics Committee for Analysis of Research
rojects on Human Experimentation.
The criterion for inclusion in the study was a complaint
f PH or AH with the intention of using a new medication
fter information about the risks and side effects. The
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Volume 55, Number 6 Wolosker et al 1697participants were specifically told that dry mouth was the
most frequent side effect and the others were minor and
fleeting. The exclusion criteria were previous glaucoma,
urinary retention, gastric retention, narrow-angle glau-
coma, and demonstrated hypersensitivity to the drug sub-
stance or other components of the product.
This was a prospective, randomized, and controlled
study. From January to June 2011, 50 consecutive patients
with PH or AH were included. Of these, 25 patients were
assigned for treatment with oxybutynin and 25 for placebo.
Three patients from the placebo group (PG) and two from
the oxybutynin group (OG) were lost to follow-up. All
patients were evaluated on two occasions: before the med-
ication was prescribed and after 6 weeks of treatment.
The PG patients were sex-matched and age-matched
with the OG patients. The distribution of age, sex, and
hyperhidrosis site is summarized in Table I. In addition to
PH and AH, 12 OG patients and 15 PG patients presented
with plantar hyperhidrosis as well.
Oxybutynin was prescribed for 6 weeks in progressively
increasing doses throughout treatment. At their first visit,
the patients were given 2.5 mg to be taken once daily in the
evening. They were instructed to increase the dose to 2.5
mg twice daily from days 8 to 21. After this period, patients
had a second visit, and the oxybutynin dose was increased
to 5 mg twice daily from day 22 to the end of the day 42,
when a third visit was scheduled. The PG received the same
instructions.
After inclusion, the patients were asked to complete a
validated questionnaire about the negative effect of hyper-
hidrosis on their quality of life (QOL) using a protocol17
that was adapted to English.18 After 6 weeks of treatment,
patients were asked to complete two additional question-
naires: one about improvement in the symptoms, including
side effects, and other about improvement in QOL. They
evaluated improvement in hyperhidrosis on a scale from 0
(no improvement) to 10 (absence of hyperhidrosis), based
on their own estimates without any intervention or advice
Table I. Age, sex, and hyperhidrosis site distribution in
each study group
Variable
Placebo Oxybutynin
P(n  22) (n  23)
Age, years
Median (range) 28.0 (18-48) 25.5 (18-50) . . .
Mean  SD 28.0  9.0 28.4  9.4 .08956a
Sex, No.
Male 6 6 . . .
Female 16 17 .928b
Hyperidrosis site,
No.
Palmar 10 11 . . .
Axillary 12 12 .873b
SD, Standard deviation.
aP value was obtained by Student t-test.
bP value was obtained by 2 test.from the interviewer. For data analysis, the improvement sas recorded as null or slight when it was 0 to 4, moderate
hen it was 5 to 7, or great when it was 8 to 10.
The negative effect of hyperhidrosis on QOL before
he treatment was classified into five levels and calculated as
he summed total score from the protocol (range, 20-100).
igher levels indicated greater severity and poorer QOL.
hen the total was 84, the QOL was considered as very
oor; from 68 to 83, poor; from 52 to 67, good; from 36 to
1, very good; and from 20 to 35, excellent.
Improvement of QOL after the treatment was also
lassified using five levels. When the total was 84, the
OL was considered as much worse; from 68 to 83, a little
orse; from 52 to 67, the same; from 36 to 51, a little
etter; and from 20 to 35, much better.
Patients evaluated the presence of dry mouth on a scale
rom 0 to 3, where 0 represented absence; 1, mild; 2,
oderate; and 3, severe.
The following parameters were studied: evolution of
H and AH, evolution of hyperhidrosis at the feet, negative
ffect of hyperhidrosis on QOL before the treatment, im-
rovement in QOL after the treatment, complications, and
ide effects.
Statistical analysis. The 2 test was performed to
erify the association between categoric variables in contin-
ency tables, and the Student t-test was used to compare
ge and study group. The significance level considered for
ll statistical tests was 0.05.
ESULTS
The evolution of PH and AH for both groups is pre-
ented in Table II. A significant association was observed
etween the evolution and study groups, with70% of OG
atients experiencing moderate or great improvement in
H or AH, whereas only 27.3% of PG patients had mod-
rate improvement (P  .001). The evolution of plantar
yperhidrosis for both groups is presented in Table III. A
ignificant association was observed between the evolution
nd study groups, with more than 90% of the OG patients
xperiencing moderate or great improvement in plantar
yperhidrosis, whereas only 13.4% of PG patients had
oderate improvement (P  .001).
The effect of hyperhidrosis on QOL before the treat-
ent is presented in Table IV. Before the treatment, all
atients fell into the poor or very poor categories; a non-
able II. Evolution of palmar or axillary hyperhidrosis,
r both
volution
Placebo Oxybutynin
PaNo. (%) No. (%)
orse (0.0) 0 (0.0) .001
ull/slight 16 (72.7) 6 (26.1) . . .
oderate 6 (27.3) 6 (26.1) . . .
reat 0 (0.0) 11 (47.8) . . .
otal 22 (100) 23 (100) . . .
P value was obtained by 2 test, excluding worse (0 cases).ignificant difference was observed between groups and
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June 20121698 Wolosker et allevels of QOL (P .426). The median QOL was 87.5 9
for PG and 91 8 for OG. The improvement in QOL after
the treatment is presented in Table V. The difference
between the OG and PG (73.9% vs 13.6%) was significant
(P  .001).
The only side effect observed in this series was the
presence of dry mouth, which is presented in Table VI.
Almost 30% of the patients in the two groups had moderate
or severe dry mouth after 3 weeks. After 6 weeks (with
higher doses), the frequency decreased for 9.1% in PG but
increased for 34.8% in OG.
DISCUSSION
The excellent results of VATS in treating patients with
PH and AHhave led to an increasing demand for treatment
worldwide.19 Most patients have been women in their early
20s because excessive sweating has greater repercussions in
women’s day-to-day lives and so they aremore likely to seek
Table III. Evolution of plantar hyperhidrosis
Evolution
Placebo Oxybutynin
PaNo. (%) No. (%)
Worse 0 (0.0) 0 (0.0) .001
Null/slight 13 (86.6) 1 (8.3) . . .
Moderate 2 (13.4) 7 (58.3) . . .
Great 0 (0.0) 4 (33.4) . . .
Total 15 (100) 12 15 (100) . . .
aP value was obtained by 2 test, considering worse  null/slight vs
moderate  great.
Table IV. Impact of hyperhidrosis on quality of life
(QOL) before the treatment
QOL before treatment
Placebo Oxybutynin
PaNo. (%) No. (%)
84-100 (very poor) 16 (72.7) 15 (65.2) .426
68-83 (poor) 6 (27.3) 8 (34.8) . . .
52-67 (good) 0 0 . . .
36-51 (very good) 0 0 . . .
20-35 (excellent) 0 0 . . .
Total 22 (100) 23 (100) . . .
aP value was obtained by 2 test, considering very poor vs poor.
Table V. Improvement in quality of life (QOL) after
treatment
Level of improvement
Placebo Oxybutynin
PaNo. (%) No. (%)
20-35 (much better) 0 8 (34.8) .001
36-51 (a little better) 3 (13.6) 9 (39.1)
52-67 (the same) 19 (86.4) 6 (26.1)
68-83 (a little worse) 0 0
84-100 (much worse) 0 0
Total 22 (100) 23 (100)
aP value was obtained by 2 test.treatment.20 The symptoms usually start during child- tood,21 and they look for treatment when they are young
dults.
Patients whose urinary disorders are treated using oxy-
utynin take larger doses (15 mg/d) than those used to
reat hyperhidrosis (10 mg/d) and may experience side
ffects of greater severity (dry mouth, headache, and urine
etention).22 We decided to start the treatment with very
ow doses of oxybutynin (2.5 mg/d) and to progressively
ncrease the dose up to 10 mg/d, because patients with
rinary disorders who start treatment with 10mg/d usually
eel severe mouth dryness at the onset of treatment.
In this study, the application of the placebo, a pharma-
ologically inert substance that produces similar effects to
hat would be expected, made it possible to distinguish the
harmacologic results and side effects from those that were
ot caused by the drug. We found that the incidence of dry
outh was similar to the placebo effect only in the begin-
ing of the treatment. In this phase (until day 21), with a
inimum dose of oxybutynin, the incidence of severe or
oderate dry mouth was30% in both groups. This effect
emonstrates the power of verbal instructions about this
ollateral effect and probably demonstrates that every indi-
idual feels thirst during the day at certain moments and
nconsciously ingests liquids to quench their thirst, and it
lso demonstrates that patients may pay more attention to
he regular sensation of thirst because of these instructions.
f we had told them that another specific effect was likely, it
robably would have been reported by the patients.
With the increase of the dosage, 34.8% of the patients
sing 10 mg of oxybutynin had the sensation of moderate
r severe dry mouth, whereas the placebo’s effect of dry
outh decreased to 9.1% (final placebo effect). Oxybu-
ynin was well tolerated despite this symptom (dry mouth),
nd none of the patients abandoned the treatment due to
his symptom. Additional data to this study are that after
he protocol period, 50% of the patients (those who had
mproved and did not want to undergo an operation)
ontinued using the medication, and dry mouth was not an
mpeding factor.
These patients with hyperhidrosis described great dis-
ontent with their PH or AH in our specific QOL ques-
ionnaire on hyperhidrosis,23 which has been validated and
sed in several published studies.24 The degree to which
yperhidrosis lowers a patient’s QOL depends on the se-
erity of the condition and the patient’s adaptation to each
ituation.25 Some individuals with milder hyperhidrosis
eport a very poor QOL, whereas others with very severe
yperhidrosis may report that their QOL is not so poor
ecause they have adapted better. All patients treated in this
tudy reported poor or very poor QOL.
Almost all patients in good clinical condition, except
hose with glaucoma, can be treated with oxybutynin. This
ncludes obese patients who might have a greater risk of
ompensatory hyperhidrosis after surgery and a higher sur-
ical risk.26
We used a nonobjective measurement of sudoresis in
hich the patients consider the amount of sweating and
heir daily experience instead of the objective methods
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in time. There is no method capable of measuring hyperhi-
drosis during an entire day. For this reason, we asked the
patients to grade their improvement on a scale from 0 to 10
for each of the sites of their hyperhidrosis complaint. After
all, hyperhidrosis is a disturbing—but not dangerous—
disease, so the goal of any treatment is the patient’s subjec-
tive improvement.
The results after treating PH and AH with oxybutynin
were satisfactory. Palmar and axillary sudoresis were de-
creased in 80%, and QOL improved in 74.6%. We also
observed that the placebo effect (27% of moderate im-
provement and no big improvement) was exceedingly in-
ferior to the therapeutic effect of oxybutynin. When VATS
is performed, the results are even better: 95% of the
patients become free from PH.27 However, this improve-
ment is often at the cost of compensatory hyperhidrosis, an
irreversible increase in sudoresis at other points of the
body.28Most of the patients in our study had hyperhidrosis
at other sites, predominantly on the feet. An additional
benefit is that the drug treatment led to a great improve-
ment at all of the other sites with hyperhidrosis (90% of
moderate or great improvement).
Limitations of this study are the small number of pa-
tients entered into each arm of the trial, with the further
reduction in patient numbers by those lost to follow-up,
and the relatively short-duration study period of 6 weeks,
which did not allow us to study the presence of tachyphy-
laxis. A larger number of patients would have given a more
accurate idea about the efficiency of this medication and
allowed us to separate patients with AH and patients with
PH. The loss of patients is always unwelcome, but in this
study, it was acceptable to be similar to other studies.
Finally, a study of patients using oxybutynin for a longer
period will provide an idea of how they evolve over time,
and a longer follow-up will allow us to study the tachyphy-
laxis.
CONCLUSIONS
The prognostic factors currently associated with a
worsening of the QOL after a thoracic sympathectomy to
treat hyperhidrosis are surgical failure and severe compen-
satory hyperhidrosis.29 In contrast, with clinical treatment,
we did not observe any worsening of the QOL. When the
treatment did not work, QOL remained unchanged. If a
patient desires that the medication be discontinued in favor
of surgical treatment, this can be done provided the patient
Table VI. Distribution of dry mouth among patients acco
Distribution
5 mg, No. (%
Placebo
Absent and mild 15 (68.2)
Moderate and severe 7 (31.8)
P (2 test) .672is properly assessed and informed regarding the most im-ortant side effect of the surgical procedure (ie, compensa-
ory hyperhidrosis).
The use of oxybutynin is a good therapeutic alternative
or the initial treatment of PH or AH. In choosing this
reatment, patients have nothing to lose, and the treatment
ay facilitate their preparation for facing future invasive
rocedures. Treatment of PH and AH with oxybutynin is a
ood initial alternative for treatment given that it presents
ood results and improves QOL.
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